Live Feeds
● TRACKER Updated 26d ago · 23 sources tracked

🔎 Under the Radar: Kodiak Stock Surges as Eye Drug Matches Regeneron’s

Kodiak Sciences stock has seen a sharp re-rating after the company presented first-time scientific results from its pivotal Phase 3 DAYBREAK trial and other late-stage programs at the American Academy of Ophthalmology 2026 meeting. The company's share price rose 167.11% over the last 30 days and 238.66% year-to-date. These trial results showed that Zenkuda and tabirafusp ted achieved vision gains non-inferior to aflibercept at one year, positioning the drugs against the current standard of care for wet age-related macular degeneration.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (23)
⚡ Key Developments & Real-Time Context
Text size:
  • âś“ Kodiak Sciences presented Phase 3 DAYBREAK trial results at the American Academy of Ophthalmology 2026 meeting.
  • âś“ Zenkuda and tabirafusp ted showed vision gains non-inferior to aflibercept at one year.
  • âś“ The 30-day share price return for Kodiak Sciences is 167.11%.
  • âś“ The year-to-date share price return for Kodiak Sciences is 238.66%.
🛡️ Source Corroboration: 23 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

The update adds specific stock performance data showing a 30-day return of 167.11% and a year-to-date return of 238.66%.

Live updates

  1. Kodiak Sciences shares surge following Phase 3 DAYBREAK trial results

    Kodiak Sciences stock has seen a sharp re-rating after the company presented first-time scientific results from its pivotal Phase 3 DAYBREAK trial and other late-stage programs at the American Academy of Ophthalmology 2026 meeting. The company's share price rose 167.11% over the last 30 days and 238.66% year-to-date. These trial results showed that Zenkuda and tabirafusp ted achieved vision gains non-inferior to aflibercept at one year, positioning the drugs against the current standard of care for wet age-related macular degeneration.

    Why it matters

    Kodiak is targeting retinal vein occlusion, diabetic retinopathy, and wet age-related macular degeneration. The company plans to file a Biologics License Application for these treatments. Success in these indications would challenge established market leaders in ophthalmology.

    What is confirmed

    • Kodiak Sciences presented Phase 3 DAYBREAK trial results at the American Academy of Ophthalmology 2026 meeting.
    • Zenkuda and tabirafusp ted showed vision gains non-inferior to aflibercept at one year.
    • The 30-day share price return for Kodiak Sciences is 167.11%.
    • The year-to-date share price return for Kodiak Sciences is 238.66%.

    Still unconfirmed

    • 54% of patients showed durability at six months as of September 28, 2026.
    • Kodiak Sciences intends to file a Biologics License Application for the treatment of retinal vein occlusion, diabetic retinopathy, and wet age-related macular degeneration.

    What to watch next

    • Submission of the Biologics License Application to regulatory bodies
    • Release of detailed data from other late-stage programs mentioned at the AAO meeting
    Sources used for this update (2)
    1. www.zacks.com — Can Zenkuda's Multi-Indication Potential Drive KOD Stock ...
    2. simplywall.st — Kodiak Sciences (KOD), What Is Behind The Latest Move?
    confidence 90%
  2. Kodiak Sciences Shares Rise Following Zenkuda Phase 3 Trial Results

    Kodiak Sciences reported Phase 3 DAYBREAK trial data showing that Zenkuda and tabirafusp ted achieved vision gains non-inferior to aflibercept at one year. These results, presented at the American Academy of Ophthalmology 2026 meeting in New Orleans, position the drugs against the current standard of care for wet age-related macular degeneration. Data from September 28, 2026, indicates 54% of patients showed durability at six months. The company intends to file a Biologics License Application for the treatment of retinal vein occlusion, diabetic retinopathy, and wet age-related macular degeneration.

    Why it matters

    Aflibercept currently serves as the established standard of care for these ocular conditions. Matching its efficacy allows Kodiak to compete directly in a high-value pharmaceutical market. The company is now moving toward regulatory approval via the BLA process.

    What is confirmed

    • Zenkuda and tabirafusp ted achieved non inferior vision gains to aflibercept at one year in the DAYBREAK trial.
    • Kodiak Sciences presented late stage clinical data for Zenkuda, tabirafusp ted, and KSI-101 at the American Academy of Ophthalmology 2026 meeting in New Orleans.

    Still unconfirmed

    • 54% of patients showed durability at six months in the DAYBREAK trial.
    • Phase 1b APEX results were presented at the American Academy of Ophthalmology 2026 meeting.

    What to watch next

    • Submission of the Biologics License Application to the FDA
    • FDA decision on the BLA for Zenkuda
    Sources used for this update (2)
    1. simplywall.st — How Investors May Respond To Kodiak Sciences Stock After Wet ...
    2. wallstreetwaves.com — Unlocking Biotech Profits: The Calendar Strategy and Key ...
    confidence 90%
  3. Kodiak Sciences Stock Surges on Positive Zenkuda Trial Data

    Kodiak Sciences' stock has risen sharply after releasing positive Phase 3 trial data for its eye drug Zenkuda, showing non-inferior vision gains to aflibercept. The company plans to submit a Biologics License Application (BLA) for Zenkuda to treat wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Analysts have revised their expectations, and insiders have made significant purchases.

    Why it matters

    The surge in Kodiak Sciences' stock comes after the company reported positive Phase 3 trial data for Zenkuda, which is being developed to treat various eye conditions. The trial data showed that Zenkuda had non-inferior vision gains compared to aflibercept, a drug developed by Regeneron. This development is significant for Kodiak Sciences as it moves closer to bringing Zenkuda to market.

    What is confirmed

    • Kodiak Sciences' Zenkuda met primary endpoints in the Phase 3 DAYBREAK study in wet AMD.
    • Zenkuda showed non-inferior Year 1 vision gains versus aflibercept.
    • Kodiak Sciences plans to submit a Biologics License Application (BLA) for Zenkuda.
    • Kodiak Sciences' stock has risen sharply after releasing positive Phase 3 trial data for Zenkuda.

    What to watch next

    • Kodiak Sciences' presentation of Zenkuda data at AAO 2026
    • FDA review of Zenkuda's Biologics License Application (BLA)
    • Regeneron's response to Zenkuda's trial data
    Sources used for this update (5)
    1. simplywall.st — How Investors May Respond To Kodiak Sciences Stock As Phase 3 ...
    2. www.distillintelligence.com — Latest Regeneron News & Announcements | Distill
    3. stockstotrade.com — KOD Stock Soars As Zenkuda Trial Fuel Sparks Massive Re ...
    4. www.timothysykes.com — KOD Stock Rockets As DAYBREAK Trial Rewrites Biotech Expectations
    5. www.marketscreener.com — Kodiak Sciences Inc. Stock (KOD) - Quote Nasdaq- MarketScreener
    confidence 100%
  4. Kodiak Sciences Stock Surges on Positive Zenkuda Trial Data

    Kodiak Sciences' stock has risen sharply after releasing positive Phase 3 trial data for its eye drug Zenkuda, which showed non-inferior vision gains to aflibercept. The company plans to submit a Biologics License Application (BLA) for Zenkuda to treat wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Analysts have revised their expectations, and insiders have made significant purchases.

    Why it matters

    Kodiak Sciences is developing treatments for high-prevalence retinal diseases using a single long-acting platform. The company's stock has grown significantly over the past year, from under $11 to over $100. The positive trial data has sparked optimism about Zenkuda's commercial potential.

    What is confirmed

    • Kodiak Sciences' stock has increased sharply after positive Phase 3 data for its retinal-disease drug candidate Zenkuda
    • The company plans to submit a Biologics License Application (BLA) for Zenkuda to treat wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion
    • Kodiak Sciences reported 54 percent six-month dosing in its September 28, 2026, DAYBREAK study
    • Q2 net loss reached USD 65.64 million

    Still unconfirmed

    • valuation and financing risks remain

    What to watch next

    • Kodiak Sciences' BLA submission for Zenkuda
    • AAO 2026 ophthalmology meeting
    • future commercial launch of Zenkuda
    Sources used for this update (4)
    1. www.marketbeat.com — KOD News Today | Why did Kodiak Sciences stock go up today? $KOD
    2. www.ad-hoc-news.de — Kodiak Sciences stock gets closer to a BLA after DAYBREAK data
    3. www.quiverquant.com — Kodiak Sciences Rises as Investors Focus on Fresh Clinical ...
    4. simplywall.st — Is Kodiak Sciences (KOD) Fully Valued As AAO 2026 Trial Data ...
    confidence 85%
  5. Kodiak Sciences Plans Three-Indication BLA After Phase 3 Trial Success

    Kodiak Sciences intends to submit a Biologics License Application (BLA) for Zenkuda to treat wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. This move follows the Phase 3 DAYBREAK trial, where Zenkuda and tabirafusp-ted met primary endpoints by demonstrating vision gains non-inferior to aflibercept. The company's stock has seen significant growth, rising from under $11 one year ago to over $100 currently. Kodiak is utilizing a single long-acting platform to target these three high-prevalence retinal diseases.

    Why it matters

    The company is positioning itself to compete with established treatments like Regeneron's Eylea and Vabysmo. Success across multiple indications would allow Kodiak to leverage one platform for a broader patient base. The stock's rapid ascent reflects investor confidence in these clinical results.

    What is confirmed

    • The Phase 3 DAYBREAK trial met primary endpoints for Zenkuda and tabirafusp-ted.
    • Zenkuda and tabirafusp-ted showed vision gains non-inferior to aflibercept.
    • Kodiak Sciences stock traded below $11 one year ago and above $100 the next.

    What to watch next

    • FDA acceptance of the three-indication BLA for Zenkuda
    • Official approval dates for the candidates
    • Comparative safety data for diabetic retinopathy and retinal vein occlusion
    Sources used for this update (3)
    1. finance.yahoo.com — This week in charts: Kodiak’s big comeback and Hengrui’s ...
    2. www.abcmoney.co.uk — KOD Stock Surged 600% in a Year — Here's Why Biotech ...
    3. simplywall.st — Learn Why The Bull Case For Kodiak Sciences Stock Could ...
    confidence 95%
  6. Kodiak Sciences Stock Surges as Eye Drug Matches Regeneron's Eylea

    Kodiak Sciences' stock has surged up to 178% after its eye disease drugs, Zenkuda and tabirafusp-ted, matched Regeneron's Eylea in a phase 3 trial for wet age-related macular degeneration. The drugs met the primary endpoint of vision improvement at one year, with Zenkuda showing 7.2 letters improvement versus 7.6 for Eylea. Kodiak plans to seek approval of one of the candidates, potentially competing with Eylea and Vabysmo.

    Why it matters

    Kodiak Sciences' successful phase 3 trial results position the company as a significant competitor to Regeneron's blockbuster drug Eylea in the wet age-related macular degeneration market. The trial, called DAYBREAK, tested two experimental drugs: Zenkuda (tarcocimab tedromer) and tabirafusp alfa tedromer (KSI-501).

    What is confirmed

    • Kodiak Sciences' stock surged up to 178% after positive phase 3 trial results.
    • Zenkuda and tabirafusp-ted matched Eylea in vision improvement at one year in a phase 3 trial.
    • Zenkuda showed 7.2 letters improvement versus 7.6 for Eylea in the trial.
    • Kodiak plans to seek approval of one of the candidates, potentially competing with Eylea and Vabysmo.
    • The phase 3 DAYBREAK trial tested two experimental drugs: Zenkuda and tabirafusp alfa tedromer (KSI-501).

    What to watch next

    • Kodiak Sciences' BLA filing for Zenkuda or tabirafusp-ted
    • Regulatory approval and market launch of Kodiak's eye disease drugs
    • Sales and market share performance of Kodiak's drugs compared to Eylea and Vabysmo
    Sources used for this update (15)
    1. Forbes — Kodiak Sciences Up 150% At Opening Bell After Drugs Pass Key Trial
    2. Fierce Biotech — Kodiak's stock doubles as resurrected eye disease drug matches Eylea in phase 3
    3. Yahoo Finance — Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial
    4. Investor's Business Daily — Why This Regeneron Eye Rival Just Catapulted More Than 120%
    5. WSJ — 🔎 Under the Radar: Kodiak Stock Surges as Eye Drug Matches Regeneron’s
    6. FirstWord — Kodiak surges on Phase III victory for Eylea rival in wet AMD
    7. finance.yahoo.com — Why Kodiak Sciences Skyrocketed Today
    8. www.fiercebiotech.com — Kodiak's stock doubles as resurrected eye disease drug ...
    9. www.biospace.com — Kodiak Sciences’ stock soars 166% after 2 assets ... - BioSpace
    10. finance.yahoo.com — Kodiak skyrockets on positive study data for 2 eye drugs
    11. finance.yahoo.com — Kodiak’s stock rallies on Phase III wAMD success
    12. www.talk.bio — Kodiak stock surges after two eye-drug candidates match Eylea ...
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community